Cellectar Biosciences INC NEW (CLRB)
Cellectar Biosciences, Inc. is a biotechnology company focused on the development of targeted cancer therapies using its proprietary phospholipid drug platform. The company specializes in creating novel compounds that deliver therapeutic agents directly to cancer cells, aiming to improve efficacy and reduce side effects. Cellectar's pipeline includes treatments for various oncology indications, leveraging its expertise in phospholipid chemistry and drug delivery technologies.
Company News
The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.
Monday, Cellectar Biosciences Inc (NASDAQ:CLRB) announced that iopofosine I 131 combined with external beam radiation therapy (EBRT) was safe and tolerated in a SPORE Grant-supported investigator-initiated Phase 1 trial. The twelve patients treated for locoregionally recurrent head and neck squamous cell carcinoma previously received chemoradi...
Here is how Cellectar Biosciences, Inc. (CLRB) and InMode (INMD) have performed compared to their sector so far this year.
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.